Pfizer will help manufacturer Gilead’s remdesivir. Pfizer signed a multi-year agreement to make the drug. The deal may help mitigate shortages of the treatment as COVID-19 cases rise. (Reuters)
Federal health officials work to convince the public that vaccine decisions will be based on science, not politics. Top FDA officials wrote articles and conducted interviews to explain they would approve a vaccine only after rigorous review. Meanwhile, President Donald Trump claimed a vaccine could be ready by election day. (The Washington Post)
Join us for MM&M Move Together, a five-day fitness challenge from August 24 to 28. We’re asking our community to be active, track your miles and contribute to our coast-to-coast journey, whether it’s swimming, cycling or walking. For every mile, MM&M will donate to World Central Kitchen, a nonprofit feeding families affected by COVID-19. (MM&M)
Biogen’s Alzheimer’s drug will get a fast-track review by the Food and Drug Administration. The application is the first Alzheimer’s treatment in 17 years to be reviewed. The FDA decision is expected by next March. (Reuters)
Hawaii reinstated strict coronavirus restrictions. The state beaches and parks have closed and the governor reinstated inter-island travel restrictions. Over the past week, cases in Hawaii increased by 85% from the previous week. (CNBC)
